- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03836443
Postprandial Lipotoxicity and Nonalcoholic Fatty Liver Disease (LITONAS)
March 11, 2024 updated by: Assistance Publique - Hôpitaux de Paris
Lipid Metabolism, Lipotoxicity and Nonalcoholic Fatty Liver Disease: Implication of Postprandial Cytotoxic Lipids
Nonalcoholic fatty liver disease (NAFLD) is mainly considered a nutrition-related disease and life-style/diet interventions showed some promising results.
But in spite of this, there are no available markers to efficiently guide interventions. the hypothesize put farth by the investigators is that NAFLD patients develop postprandial abnormalities of plasma lipids upon "western diet" challenge, more severe in steatohepatitis (NASH) than in pure steatosis (NAFL), promoting liver injury.
Our study aims to evaluate the presence of toxic lipids (such as free-fatty acids, ceramides, diacylglycerols, sphingolipids) in postprandial state after ingestion of a "western diet" in NAFLD patients.
Consecutive patients (group 1: NAFL patients; group 2: NASH patients) with biopsy-proven NAFLD (liver biopsy < 6 months) will be recruited during a period of 12 month.
Blood samples will be drawn at fasting, 2hours, 4hours, 6hours and 8hours after ingestion of a "western diet" meal.
Plasma lipid profiles using lipidomics, circulating markers of liver injury and inflammation will be analyzed.
the investigators will also assess the hepatotoxicity of plasma from NAFL or NASH patients in-vitro.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Factors driving progression from steatosis (NAFL) to steatohepatitis (NASH) in patients with non-alcoholic fatty liver disease (NAFLD) remain largely unknown.
Considerable data now indicate that steatosis per se is not a hepatotoxic event and may represent in fact a protective mechanism against free fatty acid (FFA)-induced toxicity.
the investigators previously showed that Kupffer cells from NASH mice accumulate more toxic lipids (ceramides, diacylglycerols, sphingolipids) enhancing their proinflammatory polarization.
Therefore, "quality" of accumulating lipids rather than "quantity" may play a central role in NAFLD progression.
This is a pilot comparative study aiming to evaluate the presence of toxic lipids (such as free-fatty acids, ceramides, diacylglycerols, sphingolipids) in postprandial state after ingestion of a "western diet" in NAFL and NASH patients.
The secondary outcomes were: to evaluate the relationship between postprandial circulating lipids and markers of liver injury and proinflammatory cytokines; to evaluate hepatotoxicity of postprandial lipids in vitro.
A total of 24 consecutive patients (group 1: 12 NAFL patients; group 2: 12 NASH patients) with biopsy-proven NAFLD (liver biopsy < 6 months) will be recruited.
A dietary evaluation covering the 2 previous weeks will be performed.
Detailed anthropometric data will be collected (body mass index, waist and hip circumferences, abdominal height, cutaneous skinfolds) and serum metabolic parameters (standard lipid profile, lipoprotein levels, fasting plasma glucose, insulin levels, C-peptide levels, hemoglobin A1c) will be evaluated.
After a 12hours overnight fast, patients will undergo an oral "western diet" test consisting in the ingestion of a high saturated fat, high refined sugar, high fructose-meal called "western diet" (800 kcal/meal).
Blood samples will be drawn at fasting and then 2, 4, 6 and 8hours after ingestion of the standard meal.
Each time plasma and serum samples will be stored at -80°C for subsequent analysis.
Lipidomics will be used to quantify each plasma lipid class (neutral lipids, phospholipids and fatty acid methyl esters).
Serum levels of cytokines will be assessed using multiple assay technology.
Markers of liver injury will be assessed (aminotransferases, Keratin 18 fragments, microRNA-122) in the serum.
Hepatocytes will be cultured with plasma from NAFL or NASH patients, and incubated overnight.
In vitro hepatotoxicity will be evaluated using TUNEL assay, MTT assay and LDH release assay.
the investigators anticipate that inflammation together with hepatocyte death will occur in NAFLD patients who develop specific postprandial plasma lipid changes with an increase in toxic lipid levels.
Such patients may develop more severe liver lesions (inflammation, fibrosis/cirrhosis) and benefit of interventions.
Identification of a toxic plasma lipid profile may help choosing the adequate diet in order to prevent deleterious lipid formation.
Identification of a toxic postprandial plasma lipid signature specific to hepatotoxicity may also serve to develop a discrimination index to be further validated in clinical practice.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Le Kremlin Bicetre, France
- Kremlin Bicêtre hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- histological proven NAFLD (liver biopsy <6 months); hospitalised or outpatients followed up for NAFLD; patients giving their consent for the study; patients covered by health insurance.
Exclusion Criteria:
- history of excessive alcohol consumption (>20 g/day for males and >10 g/day for females) or other cause of liver injury (viral hepatitis, autoimmune hepatitis, Wilson's disease, hemochromatosis, drug-induced hepatitis, or others); cirrhosis; ongoing hypolipemiant treatment; diabetes; Chronic diarrhea; severe associated disease;Taking antibiotics or probiotics in the last 3 months; Chronic inflammatory bowel disease; Weight ≤70Kg and hemoglobin level ≤7g/dl; Allergy to or refusal of any of the elements of the meal provided.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: NAFL patients (group 1)
A "western diet" meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal).
|
A "western diet" meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal) after an overnight fast.
|
|
Active Comparator: NASH patients (group 2)
A "western diet" meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal).
|
A "western diet" meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal) after an overnight fast.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postprandial changes of plasma lipid fractions measured by lipidomic analysis and expressed as nmolof lipid/ml
Time Frame: Plasma samples will be collected at 2hours, 4hours, 6hours and 8hours after ingestion of the "western diet" meal to assess postprandial lipid fraction changes
|
Lipidomic analysis of plasma lipid fractions expressed in ηm/ml after 12 hours of fasting and in the postprandial period (2h, 4h, 6h, 8h).
|
Plasma samples will be collected at 2hours, 4hours, 6hours and 8hours after ingestion of the "western diet" meal to assess postprandial lipid fraction changes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cytotoxic effect of postprandial plasma on hepatocytes in-vitro
Time Frame: Plasma samples at 2hours, 4hours, 6hours and 8hours after ingestion of the "western diet" meal.
|
Hepatocytes will be cultured with postprandial plasma from NAFL or NASH patients, and incubated overnight.
In-vitro hepatotoxicity will be evaluated using TUNEL assay, MTT assay and LDH release assay.
|
Plasma samples at 2hours, 4hours, 6hours and 8hours after ingestion of the "western diet" meal.
|
|
Circulating markers of liver injury (AST, ALT, cytokeratin 18 fragments, microRNA-122) and serum cytokines (TNF-α, IL-6, IL-1β, IL-8).
Time Frame: After a 12hours overnight fast and then at 2, 4, 6 and 8hours after ingestion of the "western diet" meal.
|
Circulating markers of liver injury (AST, ALT, cytokeratin 18 fragments, microRNA-122) and serum cytokines (TNF-α, IL-6, IL-1β, IL-8) will be measured after 12 hours of fasting and in the postprandial period (2h, 4h, 6h, 8h) in patients with NAFLD
|
After a 12hours overnight fast and then at 2, 4, 6 and 8hours after ingestion of the "western diet" meal.
|
|
The effect of supernatants from hepatocyte cultures exposed to patient plasma on human macrophages in vitro
Time Frame: Plasma samples at 2hours, 4hours, 6hours and 8hours after ingestion of the "western diet" meal.
|
Human macrophage will be cultured in vitro with supernatants from hepatocyte cultures exposed to patient plasma
|
Plasma samples at 2hours, 4hours, 6hours and 8hours after ingestion of the "western diet" meal.
|
|
Bacterial microbiome profiles
Time Frame: The day before or the morning before ingestion of the "western diet" meal.
|
Bacterial microbiome profiles will be measured by the pyrosequencing technique of 16S RNA
|
The day before or the morning before ingestion of the "western diet" meal.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Cosmin VOICAN, AP-HP, Beclere Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 14, 2019
Primary Completion (Actual)
June 22, 2023
Study Completion (Actual)
June 22, 2023
Study Registration Dates
First Submitted
January 17, 2019
First Submitted That Met QC Criteria
February 8, 2019
First Posted (Actual)
February 11, 2019
Study Record Updates
Last Update Posted (Actual)
March 13, 2024
Last Update Submitted That Met QC Criteria
March 11, 2024
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D20180507
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.